Deleterious versus protective autoimmunity in multiple sclerosis

Cellular Immunology

Volumn 296, Issue 2, 2015, Pages 122-132

  Kostic, Milos ^a   Stojanovic, Ivana ^a   Marjanovic, Goran ^a   Zivkovic, Nikola ^a   Cvetanovic, Ana ^b  

^a UNIVERSITY OF NI   (Serbia)

^b Clinical Centre   (Serbia)

Author keywords

Multiple sclerosis; Protective autoimmunity; Regulatory T cells; Th1 cells; Th17 cells; Th2 cells; Th9 cells

Indexed keywords

AUTOIMMUNITY; HUMAN; IMMUNOPATHOGENESIS; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH17 CELL; TH9 CELL; ANIMAL; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; IMMUNOLOGY; MOUSE; MYELIN SHEATH; PATHOLOGY; TH2 CELL;

CYTOKINE;

ANIMALS; AUTOIMMUNITY; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CYTOKINES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; MICE; MULTIPLE SCLEROSIS; MYELIN SHEATH; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS; TH2 CELLS;

EID: 84942574409     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2015.04.006     Document Type: Review

References (182)

1. [1] Sospedra, M., Martin, R., Immunology of multiple sclerosis. Annu. Rev. Immunol. 23 (2005), 683–747.
2. [2] Markovic-Plese, S., Fukaura, H., Zhang, J., al-Sabbagh, A., Southwood, S., Sette, A., Kuchroo, V.K., Hafler, D.A., T cell recognition of immunodominant and cryptic proteolipid protein epitopes in humans. J. Immunol. 155 (1997), 982–992.
3. [3] Zhang, J., Markovic-Plese, S., Lacet, B., Raus, J., Weiner, H.L., Hafler, D.A., Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J. Exp. Med. 179 (1994), 973–984.
4. [4] Fabriek, B.O., Zwemmer, J.N., Teunissen, C.E., Dijkstra, C.D., Polman, C.H., Laman, J.D., Castelijns, J.A., In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology. J. Neuroimmunol. 161 (2005), 190–194.
5. [5] de Vos, A.F., van Meurs, M., Brok, H.P., Boven, L.A., Hintzen, R.Q., van der Valk, P., Ravid, R., Rensing, S., Boon, L., ‘t Hart, B.A., Laman, J.D., Transfer of central nervous system autoantigens and presentation in secondary lymphoid organs. J. Immunol. 169 (2002), 5415–5423.
6. [6] Furtado, G.C., Marcondes, M.C., Latkowski, J.A., Tsai, J., Wensky, A., Lafaille, J.J., Swift entry of myelin-specific T lymphocytes into the central nervous system in spontaneous autoimmune encephalomyelitis. J. Immunol. 181 (2008), 4648–4655.
7. [7] van Zwam, M., Huizinga, R., Heijmans, N., van Meurs, M., Wierenga-Wolf, A.F., Melief, M.J., Hintzen, R.Q., ‘t Hart, B.A., Amor, S., Boven, L.A., Laman, J.D., Surgical excision of CNS-draining lymph nodes reduces relapse severity in chronic-relapsing experimental autoimmune encephalomyelitis. J. Pathol. 217 (2009), 543–551.
8. [8] Delogu, L.G., Deidda, S., Delitala, G., Manetti, R., Infectious diseases and autoimmunity. J. Infect. Dev. Ctries. 5 (2011), 679–687.
9. [9] Buljevac, D., Flach, H.Z., Hop, W.C., Hijdra, D., Laman, J.D., Savelkoul, H.F., van Der Meché, F.G., van Doorn, P.A., Hintzen, R.Q., Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 125 (2002), 952–960.
10. [10] Brown, D.A., Sawchenko, P.E., Time course and distribution of inflammatory and neurodegenerative events suggest structural bases for the pathogenesis of experimental autoimmune encephalomyelitis. J. Comp. Neurol. 502 (2007), 236–260.
11. [11] Ransohoff, R.M., Kivisäkk, P., Kidd, G., Three or more routes for leukocyte migration into the central nervous system. Nat. Rev. Immunol. 3 (2003), 569–581.
12. [12] Ransohoff, R.M., Engelhardt, B., The anatomical and cellular basis of immune surveillance in the central nervous system. Nat. Rev. Immunol. 12 (2012), 623–635.
13. [13] Pesic, M., Bartholomäus, I., Kyratsous, N.I., Heissmeyer, V., Wekerle, H., Kawakami, N., 2-photon imaging of phagocyte-mediated T cell activation in the CNS. J. Clin. Invest. 123 (2013), 1192–1201.
14. [14] Chastain, E.M., Duncan, D.S., Rodgers, J.M., Miller, S.D., The role of antigen presenting cells in multiple sclerosis. Biochim. Biophys. Acta 2011 (1812), 265–274.
15. [15] Schwartz, M., Protective autoimmunity as a T-cell response to central nervous system trauma: prospects for therapeutic vaccines. Prog. Neurobiol. 65 (2001), 489–496.
16. [16] Yoles, E., Hauben, E., Palgi, O., Agranov, E., Gothilf, A., Cohen, A., Kuchroo, V., Cohen, I.R., Weiner, H., Schwartz, M., Protective autoimmunity is a physiological response to CNS trauma. J. Neurosci. 21 (2001), 3740–3748.
17. +T cells: differentiation and functions. Clin. Dev. Immunol., 2012, 2012, 925135.
18. [18] Zhu, J., Jankovic, D., Oler, A.J., Wei, G., Sharma, S., Hu, G., Guo, L., Yagi, R., Yamane, H., Punkosdy, G., Feigenbaum, L., Zhao, K., Paul, W.E., The transcription factor T-bet is induced by multiple pathways and prevents an endogenous Th2 cell program during Th1 cell responses. Immunity 37 (2012), 660–673.
19. [19] McGhee, J.R., The world of TH1/TH2 subsets: first proof. J. Immunol. 175 (2005), 3–4.
20. [20] Ando, D.G., Clayton, J., Kono, D., Urban, J.L., Sercarz, E.E., Encephalitogenic T cells in the B10.PL model of experimental allergic encephalomyelitis (EAE) are of the Th-1 lymphokine subtype. Cell. Immunol. 124 (1989), 132–143.
21. [21] Waldburger, K.E., Hastings, R.C., Schaub, R.G., Goldman, S.J., Leonard, J.P., Adoptive transfer of experimental allergic encephalomyelitis after in vitro treatment with recombinant murine interleukin-12. Preferential expansion of interferon-gamma-producing cells and increased expression of macrophage-associated inducible nitric oxide synthase as immunomodulatory mechanisms. Am. J. Pathol. 148 (1996), 375–382.
22. [22] Renno, T., Krakowski, M., Piccirillo, C., Lin, J.Y., Owens, T., TNF-alpha expression by resident microglia and infiltrating leukocytes in the central nervous system of mice with experimental allergic encephalomyelitis. Regulation by Th1 cytokines. J. Immunol. 154 (1995), 944–953.
23. [23] Lovett-Racke, A.E., Rocchini, A.E., Choy, J., Northrop, S.C., Hussain, R.Z., Ratts, R.B., Sikder, D., Racke, M.K., Silencing T-bet defines a critical role in the differentiation of autoreactive T lymphocytes. Immunity 21 (2004), 719–731.
24. [24] Bielekova, B., Goodwin, B., Richert, N., Cortese, I., Kondo, T., Afshar, G., Gran, B., Eaton, J., Antel, J., Frank, J.A., McFarland, H.F., Martin, R., Encephalitogenic potential of the myelin basic protein peptide (amino acids 83–99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 6 (2000), 1167–1175.
25. [25] Panitch, H.S., Hirsch, R.L., Haley, A.S., Johnson, K.P., Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet 1 (1987), 893–895.
26. [26] Skurkovich, S., Boiko, A., Beliaeva, I., Buglak, A., Alekseeva, T., Smirnova, N., Kulakova, O., Tchechonin, V., Gurova, O., Deomina, T., Favorova, O.O., Skurkovic, B., Gusev, E., Randomized study of antibodies to IFN-gamma and TNF-alpha in secondary progressive multiple sclerosis. Mult. Scler. 7 (2001), 277–284.
27. [27] Vartanian, T., Li, Y., Zhao, M., Stefansson, K., Interferon-gamma-induced oligodendrocyte cell death: implications for the pathogenesis of multiple sclerosis. Mol. Med. 1 (1995), 732–743.
28. [28] Pouly, S., Becher, B., Blain, M., Antel, J.P., Interferon-gamma modulates human oligodendrocyte susceptibility to Fas-mediated apoptosis. J. Neuropathol. Exp. Neuro. 59 (2000), 280–286.
29. [29] Mizuno, T., Zhang, G., Takeuchi, H., Kawanokuchi, J., Wang, J., Sonobe, Y., Jin, S., Takada, N., Komatsu, Y., Suzumura, A., Interferon-gamma directly induces neurotoxicity through a neuron specific, calcium-permeable complex of IFN-gamma receptor and AMPA GluR1 receptor. FASEB J. 22 (2008), 1797–1806.
30. [30] Tran, E.H., Prince, E.N., Owens, T., IFN-gamma shapes immune invasion of the central nervous system via regulation of chemokines. J. Immunol. 164 (2000), 2759–2768.
31. [31] Cua, D.J., Sherlock, J., Chen, Y., Murphy, C.A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., Zurawski, S., Wiekowski, M., Lira, S.A., Gorman, D., Kastelein, R.A., Sedgwick, J.D., Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421 (2003), 744–748.
32. [32] Langrish, C.L., Chen, Y., Blumenschein, W.M., Mattson, J., Basham, B., Sedgwick, J.D., McClanahan, T., Kastelein, R.A., Cua, D.J., IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201 (2005), 233–240.
33. [33] Infante-Duarte, C., Horton, H.F., Byrne, M.C., Kamradt, T., Microbial lipopeptides induce the production of IL-17 in Th cells. J. Immunol. 165 (2000), 6107–6115.
34. [34] Harrington, L.E., Hatton, R.D., Mangan, P.R., Turner, H., Murphy, T.L., Murphy, K.M., Weaver, C.T., Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6 (2005), 1123–1132.
35. [35] Wilson, N.J., Boniface, K., Chan, J.R., McKenzie, B.S., Blumenschein, W.M., Mattson, J.D., Basham, S., Smith, K., Chen, T., Morel, F., Lecron, J.C., Kastelein, R.A., Cua, D.J., McClanahan, T.K., Bowman, E.P., de Waal Malefyt, R., Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat. Immunol. 8 (2007), 950–957.
36. [36] Bettelli, E., Korn, T., Kuchroo, V.K., Th17: the third member of the effector T cell trilogy. Curr. Opin. Immunol. 19 (2007), 652–657.
37. [37] Elyaman, W., Bradshaw, E.M., Uyttenhove, C., Dardalhon, V., Awasthi, A., Imitola, J., Bettelli, E., Oukka, M., van Snick, J., Renauld, J.C., Kuchroo, V.K., Khoury, S.J., IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc. Natl. Acad. Sci. U.S.A. 106 (2009), 12885–12890.
38. [38] Fossiez, F., Djossou, O., Chomarat, P., Flores-Romo, L., Ait-Yahia, S., Maat, C., Pin, J.J., Garrone, P., Garcia, E., Saeland, S., Blanchard, D., Gaillard, C., Das Mahapatra, B., Rouvier, E., Golstein, P., Banchereau, J., Lebecque, S., T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 183 (1996), 2593–2603.
39. [39] Jovanovic, D.V., Di Battista, J.A., Martel-Pelletier, J., Jolicoeur, F.C., He, Y., Zhang, M., Mineau, F., Pelletier, J.P., IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. J. Immunol. 160 (1998), 3513–3521.
40. [40] Kolls, J.K., Lindén, A., Interleukin-17 family members and inflammation. Immunity 21 (2004), 467–476.
41. [41] Ivanov, I.I., McKenzie, B.S., Zhou, L., Tadokoro, C.E., Lepelley, A., Lafaille, J.J., Cua, D.J., Littman, D.R., The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126 (2006), 1121–1133.
42. [42] Chung, Y., Chang, S.H., Martinez, G.J., Yang, X.O., Nurieva, R., Kang, H.S., Ma, L., Watowich, S.S., Jetten, A.M., Tian, Q., Dong, C., Critical regulation of early Th17 cell differentiation by interleukin-1 signaling. Immunity 30 (2009), 576–587.
43. [43] Santarlasci, V., Maggi, L., Capone, M., Frosali, F., Querci, V., De Palma, R., Liotta, F., Cosmi, L., Maggi, E., Romagnani, S., Annunziato, F., TGF-beta indirectly favors the development of human Th17 cells by inhibiting Th1 cells. Eur. J. Immunol. 39 (2009), 207–215.
44. [44] Hofstetter, H.H., Ibrahim, S.M., Koczan, D., Kruse, N., Weishaupt, A., Toyka, K.V., Gold, R., Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis. Cell. Immunol. 237 (2005), 123–130.
45. [45] Komiyama, Y., Naka, S., Matsuki, T., Nambu, A., Ishigame, H., Kakuta, S., Sudo, K., Iwakura, Y., IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 177 (2006), 566–573.
46. [46] Lock, C., Hermans, G., Pedotti, R., Brendolan, A., Schadt, E., Garren, H., Langer-Gould, A., Strober, S., Cannella, B., Allard, J., Klonowski, P., Austin, A., Lad, N., Kaminski, N., Galli, S.J., Oksenberg, J.R., Raine, C.S., Heller, R., Steinman, L., Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8 (2002), 500–508.
47. [47] Tzartos, J.S., Friese, M.A., Craner, M.J., Palace, J., Newcombe, J., Esiri, M.M., Fugger, L., Interleukin-17 production in central nervous system-infiltrating T cells and glial cells is associated with active disease in multiple sclerosis. Am. J. Pathol. 172 (2008), 146–155.
48. [48] Durelli, L., Conti, L., Clerico, M., Boselli, D., Contessa, G., Ripellino, P., Ferrero, B., Eid, P., Novelli, F., T-helper 17 cells expand in multiple sclerosis and are inhibited by interferon-beta. Ann. Neurol. 65 (2009), 499–509.
49. [49] Brucklacher-Waldert, V., Stuerner, K., Kolster, M., Wolthausen, J., Tolosa, E., Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 132 (2009), 3329–3341.
50. [50] Bailey, S.L., Schreiner, B., McMahon, E.J., Miller, S.D., CNS myeloid DCs presenting endogenous myelin peptides ‘preferentially’ polarize CD4+ T(H)-17 cells in relapsing EAE. Nat. Immunol. 8 (2007), 172–180.
51. [51] Laman, J.D., Weller, R.O., Drainage of cells and soluble antigen from the CNS to regional lymph nodes. J. Neuroimmune Pharmacol. 8 (2013), 840–856.
52. [52] van Zwam, M., Huizinga, R., Melief, M.J., Wierenga-Wolf, A.F., van Meurs, M., Voerman, J.S., Biber, K.P., Boddeke, H.W., Höpken, U.E., Meisel, C., Meisel, A., Bechmann, I., Hintzen, R.Q., t Hart, B.A., Amor, S., Laman, J.D., Boven, L.A., Brain antigens in functionally distinct antigen-presenting cell populations in cervical lymph nodes in MS and EAE.J. Mol. Med. (Berl.)., 87, 2009, 273–286.
53. [53] Kooi, E.J., van Horssen, J., Witte, M.E., Amor, S., Bø, L., Dijkstra, C.D., van der Valk, P., Geurts, J.J., Abundant extracellular myelin in the meninges of patients with multiple sclerosis. Neuropathol. Appl. Neurobiol. 35 (2009), 283–295.
54. [54] Acosta-Rodriguez, E.V., Rivino, L., Geginat, J., Jarrossay, D., Gattorno, M., Lanzavecchia, A., Sallusto, F., Napolitani, G., Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 8 (2007), 639–646.
55. [55] Reboldi, A., Coisne, C., Baumjohann, D., Benvenuto, F., Bottinelli, D., Lira, S., Uccelli, A., Lanzavecchia, A., Engelhardt, B., Sallusto, F., C–C chemokine receptor 6-regulated entry of TH-17 cells into the CNS through the choroid plexus is required for the initiation of EAE. Nat. Immunol. 10 (2009), 514–523.
56. [56] Flügel, A., Berkowicz, T., Ritter, T., Labeur, M., Jenne, D.E., Li, Z., Ellwart, J.W., Willem, M., Lassmann, H., Wekerle, H., Migratory activity and functional changes of green fluorescent effector cells before and during experimental autoimmune encephalomyelitis. Immunity 14 (2001), 547–560.
57. [57] Kivisäkk, P., Imitola, J., Rasmussen, S., Elyaman, W., Zhu, B., Ransohoff, R.M., Khoury, S.J., Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis. Ann. Neurol. 65 (2009), 457–469.
58. [58] Huppert, J., Closhen, D., Croxford, A., White, R., Kulig, P., Pietrowski, E., Bechmann, I., Becher, B., Luhmann, H.J., Waisman, A., Kuhlmann, C.R., Cellular mechanisms of IL-17-induced blood–brain barrier disruption. FASEB J. 24 (2010), 1023–1034.
59. [59] Saha, A., Sarkar, C., Singh, S.P., Zhang, Z., Munasinghe, J., Peng, S., Chandra, G., Kong, E., Mukherjee, A.B., The blood–brain barrier is disrupted in a mouse model of infantile neuronal ceroid lipofuscinosis: amelioration by resveratrol. Hum. Mol. Genet. 21 (2012), 2233–2244.
60. [60] Bradley, J.R., Johnson, D.R., Pober, J.S., Endothelial activation by hydrogen peroxide. Selective increases of intercellular adhesion molecule-1 and major histocompatibility complex class I. Am. J. Pathol. 142 (1993), 1598–1609.
61. [61] Kebir, H., Kreymborg, K., Ifergan, I., Dodelet-Devillers, A., Cayrol, R., Bernard, M., Giuliani, F., Arbour, N., Becher, B., Prat, A., Human TH17 lymphocytes promote blood–brain barrier disruption and central nervous system inflammation. Nat. Med. 13 (2007), 1173–1175.
62. [62] Murphy, A.C., Lalor, S.J., Lynch, M.A., Mills, K.H., Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav. Immun. 24 (2010), 641–651.
63. [63] Paintlia, M.K., Paintlia, A.S., Singh, A.K., Singh, I., Synergistic activity of interleukin-17 and tumor necrosis factor-α enhances oxidative stress-mediated oligodendrocyte apoptosis. J. Neurochem. 116 (2011), 508–521.
64. [64] Kang, Z., Wang, C., Zepp, J., Wu, L., Sun, K., Zhao, J., Chandrasekharan, U., DiCorleto, P.E., Trapp, B.D., Ransohoff, R.M., Li, X., Act1 mediates IL-17-induced EAE pathogenesis selectively in NG2+ glial cells. Nat. Neurosci. 16 (2013), 1401–1408.
65. [65] Li, Z., Li, K., Zhu, L., Kan, Q., Yan, Y., Kumar, P., Xu, H., Rostami, A., Zhang, G.X., Inhibitory effect of IL-17 on neural stem cell proliferation and neural cell differentiation. BMC Immunol., 14, 2013, 20.
66. [66] Trapp, B.D., Stys, P.K., Virtual hypoxia and chronic necrosis of demyelinated axons in multiple sclerosis. Lancet Neurol. 8 (2009), 280–291.
67. [67] Siffrin, V., Radbruch, H., Glumm, R., Niesner, R., Paterka, M., Herz, J., Leuenberger, T., Lehmann, S.M., Luenstedt, S., Rinnenthal, J.L., Laube, G., Luche, H., Lehnardt, S., Fehling, H.J., Griesbeck, O., Zipp, F., In vivo imaging of partially reversible th17 cell-induced neuronal dysfunction in the course of encephalomyelitis. Immunity 33 (2010), 424–436.
68. [68] Giuliani, F., Goodyer, C.G., Antel, J.P., Yong, V.W., Vulnerability of human neurons to T cell-mediated cytotoxicity. J. Immunol. 171 (2003), 368–379.
69. [69] Zhang, J., Ke, K.F., Liu, Z., Qiu, Y.H., Peng, Y.P., Th17 cell-mediated neuroinflammation is involved in neurodegeneration of aβ1-42-induced Alzheimer's disease model rats. PLoS ONE, 8, 2013, e75786.
70. [70] Wang, D.D., Zhao, Y.F., Wang, G.Y., Sun, B., Kong, Q.F., Zhao, K., Zhang, Y., Wang, J.H., Liu, Y.M., Mu, L.L., Wang, D.S., Li, H.L., IL-17 potentiates neuronal injury induced by oxygen-glucose deprivation and affects neuronal IL-17 receptor expression. J. Neuroimmunol. 212 (2009), 17–25.
71. [71] Shichita, T., Sugiyama, Y., Ooboshi, H., Sugimori, H., Nakagawa, R., Takada, I., Iwaki, T., Okada, Y., Iida, M., Cua, D.J., Iwakura, Y., Yoshimura, A., Pivotal role of cerebral interleukin-17-producing gammadeltaT cells in the delayed phase of ischemic brain injury. Nat. Med. 15 (2009), 946–950.
72. [72] Hamilton, J.A., Colony-stimulating factors in inflammation and autoimmunity. Nat. Rev. Immunol. 8 (2008), 533–544.
73. [73] Fleetwood, A.J., Cook, A.D., Hamilton, J.A., Functions of granulocyte-macrophage colony-stimulating factor. Crit. Rev. Immunol. 5 (2005), 405–428.
74. [74] McQualter, J.L., Darwiche, R., Ewing, C., Onuki, M., Kay, T.W., Hamilton, J.A., Reid, H.H., Bernard, C.C., Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis. J. Exp. Med. 7 (2001), 873–882.
75. [75] Ponomarev, E.D., Shriver, L.P., Maresz, K., Pedras-Vasconcelos, J., Verthelyi, D., Dittel, B.N., GM-CSF production by autoreactive T cells is required for the activation of microglial cells and the onset of experimental autoimmune encephalomyelitis. J. Immunol. 178 (2007), 39–48.
76. [76] Parajuli, B., Sonobe, Y., Kawanokuchi, J., Doi, Y., Noda, M., Takeuchi, H., Mizuno, T., Suzumura, A., GM-CSF increases LPS-induced production of proinflammatory mediators via upregulation of TLR4 and CD14 in murine microglia. J. Neuroinflammation., 9, 2012, 268.
77. [77] Carrieri, P.B., Provitera, V., De Rosa, T., Tartaglia, G., Gorga, F., Perrella, O., Profile of cerebrospinal fluid and serum cytokines in patients with relapsing-remitting multiple sclerosis: a correlation with clinical activity. Immunopharmacol. Immunotoxicol. 3 (1998), 373–382.
78. [78] Codarri, L., Gyülvészi, G., Tosevski, V., Hesske, L., Fontana, A., Magnenat, L., Suter, T., Becher, B., RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat. Immunol. 12 (2011), 560–567.
79. [79] Cousins, D.J., Lee, T.H., Staynov, D.Z., Cytokine coexpression during human Th1/Th2 cell differentiation: direct evidence for coordinated expression of Th2 cytokines. J. Immunol. 169 (2002), 2498–2506.
80. [80] El-Behi, M., Ciric, B., Dai, H., Yan, Y., Cullimore, M., Safavi, F., Zhang, G.X., Dittel, B.N., Rostami, A., The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF. Nat. Immunol. 12 (2011), 568–575.
81. [81] McGeachy, M.J., GM-CSF: the secret weapon in the T(H)17 arsenal. Nat. Immunol. 12 (2011), 521–522.
82. [82] Sonderegger, I., Iezzi, G., Maier, R., Schmitz, N., Kurrer, M., Kopf, M., GM-CSF mediates autoimmunity by enhancing IL-6-dependent Th17 cell development and survival. J. Exp. Med. 205 (2008), 2281–2294.
83. [83] Pelletier, M., Maggi, L., Micheletti, A., Lazzeri, E., Tamassia, N., Costantini, C., Cosmi, L., Lunardi, C., Annunziato, F., Romagnani, S., Cassatella, M.A., Evidence for a cross-talk between human neutrophils and Th17 cells. Blood 115 (2010), 335–343.
84. [84] Noster, R., Riedel, R., Mashreghi, M.F., Radbruch, H., Harms, L., Haftmann, C., Chang, H.D., Radbruch, A., Zielinski, C.E., IL-17 and GM-CSF expression are antagonistically regulated by human T helper cells.Sci. Transl. Med.., 6, 2014, 241ra80.
85. [85] Piper, C., Pesenacker, A.M., Bending, D., Thirugnanabalan, B., Varsani, H., Wedderburn, L.R., Nistala, K., T Cell Expression of Granulocyte-Macrophage Colony-Stimulating Factor in Juvenile Arthritis Is Contingent Upon Th17 Plasticity. Arthritis Rheumatol. 66 (2014), 1955–1960.
86. [86] Sheng, W., Yang, F., Zhou, Y., Yang, H., Low, P.Y., Kemeny, D.M., Tan, P., Moh, A., Kaplan, M.H., Zhang, Y., Fu, X.Y., STAT5 programs a distinct subset of GM-CSF-producing T helper cells that is essential for autoimmune neuroinflammation. Cell Res. 24 (2014), 1387–1402.
87. [87] Tan, C., Gery, I., The unique features of Th9 cells and their products. Crit. Rev. Immunol. 32 (2012), 1–10.
88. [88] Chang, H.C., Sehra, S., Goswami, R., Yao, W., Yu, Q., Stritesky, G.L., Jabeen, R., McKinley, C., Ahyi, A.N., Han, L., Nguyen, E.T., Robertson, M.J., Perumal, N.B., Tepper, R.S., Nutt, S.L., Kaplan, M.H., The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation. Nat. Immunol. 11 (2010), 527–534.
89. [89] Goswami, R., Jabeen, R., Yagi, R., Pham, D., Zhu, J., Goenka, S., Kaplan, M.H., STAT6-dependent regulation of Th9 development. J. Immunol. 188 (2012), 968–975.
90. [90] Veldhoen, M., Uyttenhove, C., van Snick, J., Helmby, H., Westendorf, A., Buer, J., Martin, B., Wilhelm, C., Stockinger, B., Transforming growth factor-beta ‘reprograms’ the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat. Immunol. 9 (2008), 1341–1346.
91. [91] Veldhoen, M., Uyttenhove, C., van Snick, J., Helmby, H., Westendorf, A., Buer, J., Martin, B., Wilhelm, C., Stockinger, B., Transforming growth factor-beta ‘reprograms’ the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat. Immunol. 12 (2008), 1341–1346.
92. [92] Tan, C., Aziz, M.K., Lovaas, J.D., Vistica, B.P., Shi, G., Wawrousek, E.F., Gery, I., Antigen-specific Th9 cells exhibit uniqueness in their kinetics of cytokine production and short retention at the inflammatory site. J. Immunol. 11 (2010), 6795–6801.
93. [93] Beriou, G., Bradshaw, E.M., Lozano, E., Costantino, C.M., Hastings, W.D., Orban, T., Elyaman, W., Khoury, S.J., Kuchroo, V.K., Baecher-Allan, C., Hafler, D.A., TGF-β Induces IL-9 Production from Human Th17 Cells. J. Immunol. 1 (2010), 46–54.
94. [94] Lauwerys, B.R., Garot, N., Renauld, J.C., Houssiau, F.A., Cytokine production and killer activity of NK/T-NK cells derived with IL-2, IL-15, or the combination of IL-12 and IL-18. J. Immunol. 4 (2000), 1847–1853.
95. [95] Eller, K., Wolf, D., Huber, J.M., Metz, M., Mayer, G., McKenzie, A.N.J., Maurer, M., Rosenkranz, A.R., Wolf, A.M., IL-9 production by regulatory T cells recruits mast cells that are essential for regulatory T cell-induced immune-suppression. J. Immunol. 1 (2011), 83–91.
96. [96] Purwar, R., Schlapbach, C., Xiao, S., Kang, H.S., Elyaman, W., Jiang, X., Jetten, A.M., Khoury, S.J., Fuhlbrigge, R.C., Kuchroo, V.K., Clark, R.A., Kupper, T.S., Robust tumor immunity to melanoma mediated by interleukin 9. Nat. Med. 8 (2012), 1248–1253.
97. [97] Schlapbach, C., Gehad, A., Yang, C., Watanabe, R., Guenova, E., Teague, J.E., Campbell, L., Yawalkar, N., Kupper, T.S., Clark, R.A., Human TH9 cells are skin-tropic and have autocrine and paracrine pro-inflammatory capacity.Sci. Transl. Med.., 219, 2014, 219ra8.
98. [98] Dardalhon, V., Awasthi, A., Kwon, H., Galileos, G., Gao, W., Sobel, R.A., Mitsdoerffer, M., Strom, T.B., Elyaman, W., Ho, I.C., Khoury, S., Oukka, M., Kuchroo, V.K., Interleukin 4 inhibits TGF-β-induced-Foxp3+T cells and generates, in combination with TGF-β, Foxp3− effector T cells that produce interleukins 9 and 10. Nat. Immunol. 12 (2008), 1347–1355.
99. [99] Ouyang, H., Shi, Y., Liu, Z., Feng, S., Li, L., Su, N., Lu, Y., Kong, S., Increased interleukin-9 and CD4+IL-9+ T cells in patients with systemic lupus erythematosus. Mol. Med. Rep. 7 (2013), 1031–1037.
100. [100] Singh, T.P., Schön, M.P., Wallbrecht, K., Gruber-Wackernagel, A., Wang, X.J., Wolf, P., Involvement of IL-9 in Th17-associated inflammation and angiogenesis of psoriasis. PLoS ONE, 8, 2013, e51752.
101. [101] Yanaba, K., Yoshizaki, A., Asano, Y., Kadono, T., Sato, S., Serum interleukin 9 levels are increased in patients with systemic sclerosis: association with lower frequency and severity of pulmonary fibrosis. J. Rheumatol. 38 (2011), 2193–2197.
102. [102] Jäger, A., Dardalhon, V., Sobel, R.A., Bettelli, E., Kuchroo, V.K., Th1, Th17, and Th9 effector cells induce experimental autoimmune encephalomyelitis with different pathological phenotypes. J. Immunol. 183 (2009), 7169–7177.
103. [103] Li, H., Nourbakhsh, B., Cullimore, M., Zhang, G.X., Rostami, A., IL-9 is important for T-cell activation and differentiation in autoimmune inflammation of the central nervous system. Eur. J. Immunol. 41 (2011), 2197–2206.
104. [104] Murugaiyan, G., Beynon, V., Pires Da Cunha, A., Joller, N., Weiner, H.L., IFN-g limits Th9-mediated autoimmune inflammation through dendritic cell modulation of IL-27. J. Immunol. 189 (2012), 5277–5283.
105. [105] Nowak, E.C., Weaver, C.T., Turner, H., Begum-Haque, S., Becher, B., Schreiner, B., Coyle, A.J., Kasper, L.H., Noelle, R.J., IL-9 as a mediator of Th17-driven inflammatory disease. J. Exp. Med. 206 (2009), 1653–1660.
106. [106] Kara, E.E., Comerford, I., Bastow, C.R., Fenix, K.A., Litchfield, W., Handel, T.M., McColl, S.R., Distinct chemokine receptor axes regulate Th9 cell trafficking to allergic and autoimmune inflammatory sites. J. Immunol. 191 (2013), 1110–1117.
107. [107] Zhou, Y., Sonobe, Y., Akahori, T., Jin, S., Kawanokuchi, J., Noda, M., Iwakura, Y., Mizuno, T., Suzumura, A., IL-9 promotes Th17 cell migration into the central nervous system via CC chemokine ligand-20 produced by astrocytes. J. Immunol. 186 (2011), 4415–4421.
108. [108] Li, H., Nourbakhsh, B., Ciric, B., Zhang, G.X., Rostami, A., Neutralization of IL-9 ameliorates experimental autoimmune encephalomyelitis by decreasing the effector T cell population. J. Immunol. 185 (2010), 4095–4100.
109. [109] Lucchinetti, C., Brück, W., Parisi, J., Scheithauer, B., Rodriguez, M., Lassmann, H., Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. 47 (2000), 707–717.
110. [110] Breij, E.C., Brink, B.P., Veerhuis, R., van den Berg, C., Vloet, R., Yan, R., Dijkstra, C.D., van der Valk, P., Bö, L., Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann. Neurol. 63 (2008), 16–25.
111. [111] Das Sarma, J., Ciric, B., Marek, R., Sadhukhan, S., Caruso, M.L., Shafagh, J., Fitzgerald, D.C., Shindler, K.S., Rostami, A., Functional interleukin-17 receptor A is expressed in central nervous system glia and upregulated in experimental autoimmune encephalomyelitis.J. Neuroinflammation., 6, 2009, 14.
112. [112] Sofroniew, M.V., Multiple roles for astrocytes as effectors of cytokines and inflammatory mediators. Neuroscientist 20 (2014), 160–172.
113. [113] Kawanokuchi, J., Shimizu, K., Nitta, A., Yamada, K., Mizuno, T., Takeuchi, H., Suzumura, A., Production and functions of IL-17 in microglia. J. Neuroimmunol. 194 (2008), 54–61.
114. [114] Yan, Y., Ding, X., Li, K., Ciric, B., Wu, S., Xu, H., Gran, B., Rostami, A., Zhang, G.X., CNS-specific therapy for ongoing EAE by silencing IL-17 pathway in astrocytes. Mol. Ther. 20 (2012), 1338–1348.
115. [115] Dheen, S.T., Kaur, C., Ling, E.A., Microglial activation and its implications in the brain diseases. Curr. Med. Chem. 14 (2007), 1189–1197.
116. [116] Barbierato, M., Facci, L., Argentini, C., Marinelli, C., Skaper, S.D., Giusti, P., Astrocyte-microglia cooperation in the expression of a pro-inflammatory phenotype. CNS Neurol. Disord.: Drug Targets 12 (2013), 608–618.
117. [117] Dutta, R., Trapp, B.D., Pathogenesis of axonal and neuronal damage in multiple sclerosis. Neurology 68 (2007), 22–31.
118. [118] Patel, J., Balabanov, R., Molecular mechanisms of oligodendrocyte injury in multiple sclerosis and experimental autoimmune encephalomyelitis. Int. J. Mol. Sci. 13 (2012), 10647–10659.
119. [119] di Penta, A., Moreno, B., Reix, S., Fernandez-Diez, S., Villanueva, M., Errea, O., Escala, N., Vandenbroeck, K., Comella, J.X., Villoslada, P., Oxidative stress and proinflammatory cytokines contribute to demyelination and axonal damage in a cerebellar culture model of neuroinflammation. PLoS ONE, 8, 2013, e54722.
120. [120] Heppner, F.L., Greter, M., Marino, D., Falsig, J., Raivich, G., Hövelmeyer, N., Waisman, A., Rülicke, T., Prinz, M., Priller, J., Becher, B., Aguzzi, A., Experimental autoimmune encephalomyelitis repressed by microglial paralysis. Nat. Med. 11 (2005), 146–152.
121. [121] Lassmann, H., Mechanisms of inflammation induced tissue injury in multiple sclerosis. J. Neurol. Sci. 274 (2008), 45–47.
122. [122] Politis, M., Giannetti, P., Su, P., Turkheimer, F., Keihaninejad, S., Wu, K., Waldman, A., Malik, O., Matthews, P.M., Reynolds, R., Nicholas, R., Piccini, P., Increased PK11195 PET binding in the cortex of patients with MS correlates with disability. Neurology 79 (2012), 523–530.
123. [123] Sabatino, G., Nicoletti, M., Neri, G., Saggini, A., Rosati, M., Conti, F., Cianchetti, E., Toniato, E., Fulcheri, M., Caraffa, A., Antinolfi, P., Frydas, S., Pandolfi, F., Potalivo, G., Galzio, R., Conti, P., Theoharides, T.C., Impact of IL-9 and IL-33 in mast cells. J. Biol. Regul. Homeost. Agents 26 (2012), 577–586.
124. [124] Toms, R., Weiner, H.L., Johnson, D., Identification of IgE-positive cells and mast cells in frozen sections of multiple sclerosis brains. J. Neuroimmunol. 2–3 (1990), 169–177.
125. [125] Secor, V.H., Secor, W.E., Gutekunst, C.A., Brown, M.A., Mast cells are essential for early onset and severe disease in a murine model of multiple sclerosis. J. Exp. Med. 191 (2000), 813–822.
126. [126] Sayed, B.A., Walker, M.E., Brown, M.A., Cutting edge: mast cells regulate disease severity in a relapsing-remitting model of multiple sclerosis. J. Immunol. 186 (2011), 3294–3298.
127. [127] Axtell, R.C., de Jong, B.A., Boniface, K., van der Voort, L.F., Bhat, R., De Sarno, P., Naves, R., Han, M., Zhong, F., Castellanos, J.G., Mair, R., Christakos, A., Kolkowitz, I., Katz, L., Killestein, J., Polman, C.H., de Waal Malefyt, R., Steinman, L., Raman, C., T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat. Med. 16 (2010), 406–412.
128. [128] Segal, B.M., Constantinescu, C.S., Raychaudhuri, A., Kim, L., Fidelus-Gort, R., Kasper, L.H., Ustekinumab MS Investigators, Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 7 (2008), 796–804.
129. [129] Peck, A., Mellins, E.D., Plasticity of T-cell phenotype and function: the T helper type 17 example. Immunology 129 (2010), 147–153.
130. [130] Duhen, R., Glatigny, S., Arbelaez, C.A., Blair, T.C., Oukka, M., Bettelli, E., Cutting edge: the pathogenicity of IFN-γ-producing Th17 cells is independent of T-bet. J. Immunol. 190 (2013), 4478–4482.
131. [131] F. Annunziato, L. Cosmil, F. Liotta, E. Maggi, S. Romagnani1, Human Th1 dichotomy: origin, phenotype and biologic activities, Immunology Accepted Article. doi: 10.1111/imm.12399.
132. [132] Moalem, G., Leibowitz-Amit, R., Yoles, E., Mor, F., Cohen, I.R., Schwartz, M., Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat. Med. 5 (1999), 49–55.
133. [133] Serpe, C.J., Coers, S., Sanders, V.M., Jones, K.J., CD4+ T, but not CD8+ or B, lymphocytes mediate facial motoneuron survival after facial nerve transection. Brain Behav. Immun. 17 (2003), 393–402.
134. [134] Kipnis, J., Yoles, E., Schori, H., Hauben, E., Shaked, I., Schwartz, M., Neuronal survival after CNS insult is determined by a genetically encoded autoimmune response. J. Neurosci. 21 (2001), 4564–4571.
135. [135] Schwartz, M., Kipnis, J., Protective autoimmunity: regulation and prospects for vaccination after brain and spinal cord injuries. Trends Mol. Med. 7 (2010), 252–258.
136. [136] Zhu, J., Transcriptional regulation of Th2 cell differentiation. Immunol. Cell Biol. 88 (2010), 244–249.
137. [137] Prass, K., Meisel, C., Höflich, C., Braun, J., Halle, E., Wolf, T., Ruscher, K., Victorov, I.V., Priller, J., Dirnagl, U., Volk, H.D., Meisel, A., Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J. Exp. Med. 198 (2003), 725–736.
138. [138] Kennedy, M.K., Torrance, D.S., Picha, K.S., Mohler, K.M., Analysis of cytokine mRNA expression in the central nervous system of mice with experimental allergic encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery. J. Immunol. 149 (1992), 2496–2505.
139. [139] La Flamme, A.C., Harvie, M., McNeill, A., Goldsack, L., Tierney, J.B., Bäckström, B.T., Fcgamma receptor-ligating complexes improve the course of experimental autoimmune encephalomyelitis by enhancing basal Th2 responses. Immunol. Cell Biol. 84 (2006), 522–529.
140. [140] Fernando, V., Omura, S., Sato, F., Kawai, E., Martinez, N.E., Elliott, S.F., Yoh, K., Takahashi, S., Tsunoda, I., Regulation of an autoimmune model for multiple sclerosis in Th2-biased GATA3 transgenic mice. Int. J. Mol. Sci. 15 (2014), 1700–1718.
141. [141] Oreja-Guevara, C., Ramos-Cejudo, J., Aroeira, L.S., Chamorro, B., Diez-Tejedor, E., TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab. BMC Neurol., 12, 2012, 95.
142. [142] Mosser, D.M., Edwards, J.P., Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8 (2008), 958–969.
143. [143] Cherry, J.D., Olschowka, J.A., O'Banion, M.K., Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J. Neuroinflammation, 11, 2014, 98.
144. [144] Zhao, W., Xie, W., Xiao, Q., Beers, D.R., Appel, S.H., Protective effects of an anti-inflammatory cytokine, interleukin-4, on motoneuron toxicity induced by activated microglia. J. Neurochem. 99 (2006), 1176–1187.
145. [145] Durafourt, B.A., Moore, C.S., Zammit, D.A., Johnson, T.A., Zaguia, F., Guiot, M.C., Bar-Or, A., Antel, J.P., Comparison of polarization properties of human adult microglia and blood-derived macrophages. Glia 60 (2012), 717–727.
146. [146] Miron, V.E., Boyd, A., Zhao, J.W., Yuen, T.J., Ruckh, J.M., Shadrach, J.L., van Wijngaarden, P., Wagers, A.J., Williams, A., Franklin, R.J., ffrench-Constant, C., M2 microglia and macrophages drive oligodendrocyte differentiation during CNS remyelination. Nat. Neurosci. 16 (2013), 1211–1218.
147. [147] Mikita, J., Dubourdieu-Cassagno, N., Deloire, M.S., Vekris, A., Biran, M., Raffard, G., Brochet, B., Canron, M.H., Franconi, J.M., Boiziau, C., Petry, K.G., Altered M1/M2 activation patterns of monocytes in severe relapsing experimental rat model of multiple sclerosis. Amelioration of clinical status by M2 activated monocyte administration. Mult. Scler. 17 (2012), 2–15.
148. [148] Sicotte, M., Tsatas, O., Jeong, S.Y., Cai, C.Q., He, Z., David, S., Immunization with myelin or recombinant Nogo-66/MAG in alum promotes axon regeneration and sprouting after corticospinal tract lesions in the spinal cord. Mol. Cell. Neurosci. 23 (2003), 251–263.
149. [149] Roy, A., Liu, X., Pahan, K., Myelin basic protein-primed T cells induce neurotrophins in glial cells via alpha5 beta3 integrin. J. Biol. Chem. 282 (2007), 32222–32232.
150. [150] Lisak, R.P., Benjamins, J.A., Bealmear, B., Nedelkoska, L., Yao, B., Land, S., Studzinski, D., Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for glial and neural-related molecules in central nervous system mixed glial cell cultures: neurotrophins, growth factors and structural proteins. J. Neuroinflammation, 4, 2007, 30.
151. [151] Stadelmann, C., Kerschensteiner, M., Misgeld, T., Brück, W., Hohlfeld, R., Lassmann, H., BDNF and gp145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells?. Brain 125 (2002), 75–85.
152. [152] Charles, P.C., Weber, K.S., Cipriani, B., Brosnan, C.F., Cytokine, chemokine and chemokine receptor mRNA expression in different strains of normal mice: implications for establishment of a Th1/Th2 bias. J. Neuroimmunol. 100 (1999), 64–73.
153. [153] Pedotti, R., Farinotti, M., Falcone, C., Borgonovo, L., Confalonieri, P., Campanella, A., Mantegazza, R., Pastorello, E., Filippini, G., Allergy and multiple sclerosis: a population-based case-control study. Mult. Scler. 15 (2009), 899–906.
154. [154] Henderson, R.D., Bain, C.J., Pender, M.P., The occurrence of autoimmune diseases in patients with multiple sclerosis and their families. J. Clin. Neurosci. 7 (2000), 434–437.
155. [155] Nielsen, N.M., Frisch, M., Rostgaard, K., Wohlfahrt, J., Hjalgrim, H., Koch-Henriksen, N., Melbye, M., Westergaard, T., Autoimmune diseases in patients with multiple sclerosis and their first-degree relatives: a nationwide cohort study in Denmark. Mult. Scler. 14 (2008), 823–829.
156. [156] Schmidt, A., Oberle, N., Krammer, P.H., Molecular mechanisms of treg-mediated T cell suppression. Front. Immunol., 3, 2012, 51.
157. [157] Sakaguchi, S., Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6 (2005), 345–352.
158. [158] Xystrakis, E., Dejean, A.S., Bernard, I., Druet, P., Liblau, R., Gonzalez-Dunia, D., Saoudi, A., Identification of a novel natural regulatory CD8 T-cell subset and analysis of its mechanism of regulation. Blood 104 (2004), 3294–3301.
159. [159] Battaglia, M., Gregori, S., Bacchetta, R., Roncarolo, M.G., Tr1 cells: from discovery to their clinical application. Semin. Immunol. 18 (2006), 120–127.
160. [160] Weiner, H.L., Induction and mechanism of action of transforming growth factor-beta-secreting Th3 regulatory cells. Immunol. Rev. 182 (2001), 207–214.
161. [161] Uss, E., Rowshani, A.T., Hooibrink, B., Lardy, N.M., van Lier, R.A., ten Berge, I.J., CD103 is a marker for alloantigen-induced regulatory CD8+ T cells. J. Immunol. 177 (2006), 2775–2783.
162. [162] Monteiro, M., Almeida, C.F., Caridade, M., Ribot, J.C., Duarte, J., Agua-Doce, A., Wollenberg, I., Silva-Santos, B., Graca, L., Identification of regulatory Foxp3+ invariant NKT cells induced by TGF-beta. J. Immunol. 185 (2010), 2157–2163.
163. [163] Koch, M.A., Tucker-Heard, G., Perdue, N.R., Killebrew, J.R., Urdahl, K.B., Campbell, D.J., The transcription factor T-bet controls regulatory T cell homeostasis and function during type 1 inflammation. Nat. Immunol. 10 (2009), 595–602.
164. [164] Zhen, Y., Chaudhry, A., Kas, A., deRoos, P., Kim, J.M., Chu, T.T., Corcoran, L., Treuting, P., Klein, U., Rudensky, A.Y., Regulatory T-cell suppressor program co-opts transcription factor IRF4 to control T(H)2 responses. Nature 458 (2009), 351–356.
165. [165] Huan, J., Culbertson, N., Spencer, L., Bartholomew, R., Burrows, G.G., Chou, Y.K., Bourdette, D., Ziegler, S.F., Offner, H., Vandenbark, A.A., Decreased FOXP3 levels in multiple sclerosis patients. J. Neurosci. Res. 81 (2005), 45–52.
166. [166] Feger, U., Luther, C., Poeschel, S., Melms, A., Tolosa, E., Wiendl, H., Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients. Clin. Exp. Immunol. 147 (2007), 412–418.
167. [167] Venken, K., Hellings, N., Thewissen, M., Somers, V., Hensen, K., Rummens, J., Medaer, R., Hupperts, R., Stinissen, P., Compromised CD4+ CD25high regulatory T-cell function in patients with relapsing-remitting multiple sclerosis is correlated with a reduced frequency of FOXP3-positive cells and reduced FOXP3 expression at the single-cell level. Immunology 123 (2008), 79–89.
168. [168] Dalla Libera, D., Di Mitri, D., Bergami, A., Centonze, D., Gasperini, C., Grasso, M.G., Galgani, S., Martinelli, V., Comi, G., Avolio, C., Martino, G., Borsellino, G., Sallusto, F., Battistini, L., Furlan, R., T regulatory cells are markers of disease activity in multiple sclerosis patients. PLoS ONE, 6, 2011, e21386.
169. [169] Haas, J., Hug, A., Viehöver, A., Fritzsching, B., Falk, C.S., Filser, A., Vetter, T., Milkova, L., Korporal, M., Fritz, B., Storch-Hagenlocher, B., Krammer, P.H., Suri-Payer, E., Wildemann, B., Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur. J. Immunol. 35 (2005), 3343–3352.
170. [170] Kumar, M., Putzki, N., Limmroth, V., Remus, R., Lindemann, M., Knop, D., Mueller, N., Hardt, C., Kreuzfelder, E., Grosse-Wilde, H., CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis. J. Neuroimmunol. 180 (2006), 178–184.
171. [171] Frisullo, G., Nociti, V., Iorio, R., Patanella, A.K., Caggiula, M., Marti, A., Sancricca, C., Angelucci, F., Mirabella, M., Tonali, P.A., Batocchi, A.P., Regulatory T cells fail to suppress CD4T+-bet+ T cells in relapsing multiple sclerosis patients. Immunology 127 (2009), 418–428.
172. [172] Fletcher, J.M., Lonergan, R., Costelloe, L., Kinsella, K., Moran, B., O'Farrelly, C., Tubridy, N., Mills, K.H., CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J. Immunol. 183 (2009), 7602–7610.
173. [173] Williams, L.M., Rudensky, A.Y., Maintenance of the Foxp3-dependent developmental program in mature regulatory T cells requires continued expression of Foxp3. Nat. Immunol. 8 (2007), 277–284.
174. [174] Liu, Y., Carlsson, R., Comabella, M., Wang, J., Kosicki, M., Carrion, B., Hasan, M., Wu, X., Montalban, X., Dziegiel, M.H., Sellebjerg, F., Sørensen, P.S., Helin, K., Issazadeh-Navikas, S., FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. Nat. Med. 20 (2014), 272–282.
175. [175] Frisullo, G., Nociti, V., Iorio, R., Plantone, D., Patanella, A.K., Tonali, P.A., Batocchi, A.P., CD8(+)Foxp3(+) T cells in peripheral blood of relapsing-remitting multiple sclerosis patients. Hum. Immunol. 71 (2010), 437–441.
176. [176] Martinez-Forero, I., Garcia-Munoz, R., Martinez-Pasamar, S., Inoges, S., Lopez-Diaz de Cerio, A., Palacios, R., Sepulcre, J., Moreno, B., Gonzalez, Z., Fernandez-Diez, B., Melero, I., Bendandi, M., Villoslada, P., IL-10 suppressor activity and ex vivo Tr1 cell function are impaired in multiple sclerosis. Eur. J. Immunol. 38 (2008), 576–586.
177. [177] Beers, D.R., Henkel, J.S., Zhao, W., Wang, J., Huang, A., Wen, S., Liao, B., Appel, S.H., Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis. Brain 134 (2011), 1293–1314.
178. [178] Reynolds, A.D., Banerjee, R., Liu, J., Gendelman, H.E., Mosley, R.L., Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease. J. Leukoc. Biol. 82 (2007), 1083–1094.
179. [179] Liu, J., Gong, N., Huang, X., Reynolds, A.D., Mosley, R.L., Gendelman, H.E., Neuromodulatory activities of CD4+CD25+ regulatory T cells in a murine model of HIV-1 associated neurodegeneration. J. Immunol. 182 (2009), 3855–3865.
180. [180] Xinqiang, S., Fei, L., Nan, L., Yuan, L., Fang, Y., Hong, X., Lixin, T., Juan, L., Xiao, Z., Yuying, S., Yongzhi, X., Therapeutic efficacy of experimental rheumatoid arthritis with low-dose methotrexate by increasing partially CD4+CD25+ Treg cells and inducing Th1 to Th2 shift in both cells and cytokines. Biomed. Pharmacother. 64 (2010), 463–471.
181. [181] Schwartz, M., Kipnis, J., Multiple sclerosis as a by-product of the failure to sustain protective autoimmunity: a paradigm shift. Neuroscientist 8 (2002), 405–413.
182. [182] Foote, A.K., Blakemore, W.F., Inflammation stimulates remyelination in areas of chronic demyelination. Brain 128 (2005), 528–539.